SCHEMBL609692

SCHEMBL609692

FC(CN1CCN(CC2CCCCC2)CC1)Cn1c2ccccc2c2cc(-c3ccccc3)ccc21

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
RAD52 P43351 1/20 0.41
POLB P06746 1/20 0.40
PTGER4 P35408 2/20 0.40
TSPO P30536 1/20 0.40
NPC1 O15118 1/20 0.39
DNM1 Q05193 1/20 0.39
TMEM97 Q5BJF2 3/20 0.38
SIGMAR1 Q99720 3/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
RORA P35398 1/20 0.38
RORC P51449 1/20 0.38
RORB Q92753 1/20 0.38
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609362 0.88 POLB (0.57) MEN1KMT2ARAD52POLBDNM1
SCHEMBL608135 0.81 RAD52 (0.48) MEN1KMT2ARAD52TSPODNM1
SCHEMBL609617 0.80 TSPO (0.52) PTGER4TSPONPC1TMEM97SIGMAR1
SCHEMBL607028 0.74 MEN1 (0.76) MEN1KMT2ARAD52POLBDNM1
SCHEMBL3848636 0.68 KDM4E (0.63) MEN1KMT2APOLBTSPODNM1
SCHEMBL607458 0.68 RAD52 (0.66) MEN1KMT2ARAD52POLBDNM1
SCHEMBL608753 0.68 RAD52 (0.75) MEN1KMT2ARAD52POLBDNM1
SCHEMBL608989 0.68 RAD52 (0.73) MEN1KMT2ARAD52POLBLMNA
SCHEMBL608297 0.68 RAD52 (0.75) MEN1KMT2ARAD52POLBDNM1
SCHEMBL5026821 0.68 RAD52 (0.75) MEN1KMT2ARAD52POLBDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US claimed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US claimed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD MEN1 3810/4885KMT2A 732/4885RAD52 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.